|Bid||97.00 x 30000|
|Ask||99.50 x 30000|
|Day's Range||96.00 - 96.50|
|52 Week Range||57.96 - 105.00|
|Beta (5Y Monthly)||0.29|
|PE Ratio (TTM)||43.47|
|Forward Dividend & Yield||0.87 (0.88%)|
|Ex-Dividend Date||Mar 10, 2020|
|1y Target Est||N/A|
Quadrivalent formulation of the first-and-only adjuvanted seasonal influenza vaccine for older adults (65+ years) receives FDA approval
Researchers at the University of Pittsburgh and the University of Delaware have been awarded funding and support to accelerate their search for new medicines through an ongoing partnership between global biotechnology leader CSL Behring and the University City Science Center.
Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted Privigen® (Immune Globulin Intravenous (Human),10% Liquid) orphan-drug designation as an investigational therapy in the treatment of Systemic Sclerosis (SSc). SSc is a chronic and potentially life-threatening autoimmune disorder characterized by a build-up of scar tissue (fibrosis) in the skin and other organs.1 It affects approximately 100,000 people in the U.S.2 There are currently no FDA-approved, disease-modifying treatments to stop or reverse the overall course of the disease.
Australian biotech company CSL Ltd on Wednesday posted an 8% rise in first-half profit and raised its earnings forecast for the full year, helped by strong demand for its immunoglobulin (IG) products. The company, which makes treatments for blood-related diseases and vaccines for influenza, posted a net profit of $1.25 billion for the six months ended Dec. 31, compared with $1.16 billion a year earlier. CSL raised its after-tax net profit forecast for the full year to a range of $2.11 billion to $2.17 billion at constant currency.
Seqirus, a global leader in influenza prevention and pandemic response, today announced that the U.S. Food and Drug Administration (FDA) has approved AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1).1 AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.2
Peer reviewed: ScienceProject funding: Australian Research Council, National Health and Medical Research Council, Cancer Council Victoria, the Victorian Cancer Agency and CSL LimitedThis study used in-vitro models
Global biotechnology giant CSL Limited, parent company of biotherapeutics leader CSL Behring and world-leading influenza provider Seqirus, will present at the 38th annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer and Managing Director Paul Perreault will present the company's overview on Monday, January 13, at 3:30 p.m. PT, (6:30 p.m. ET), at the Westin St. Francis Hotel.
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Seqirus announced today results from a prospective, cluster-randomized trial led by a team of researchers from Brown University that showed FLUAD®, an adjuvanted trivalent influenza vaccine (aTIV), was more effective than standard non-adjuvanted trivalent influenza vaccine (TIV) in reducing the risk of all-cause hospitalizations, as well as hospitalization for influenza and pneumonia, in adults 65 years and older living in United States (U.S.) nursing homes during the 2016/17 influenza season.1 These findings were presented at the recent National Foundation for Infectious Diseases (NFID) 2019 Clinical Vaccinology Course (CVC), which took place in Washington, D.C.
Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. CIDP is a rare autoimmune disorder that affects the peripheral nerves and has the potential to cause significant disability.